
ABSTRACT This study investigated unconfirmed-positive rates with the BioFire FilmArray Gastrointestinal Panel (FAGP) for bacterial targets and Norovirus and determined if melt curve analysis can mitigate unconfirmed results. Positive FAGP results for bacteria were classified as culture-positive or culture-negative and as melt curve-specific or curve-nonspecific. Culture-negative samples were prospectively confirmed with the Xpert GI PCR Panel. Norovirus-positive results were classified as melt curve-specific or curve-nonspecific and confirmed with the Xpert Norovirus PCR. The primary aim was to measure the accuracy of FAGP with and without melt curve analysis. Culture-negative rate was 24.6% (100/407) for Campylobacter jejuni , 90.1% (100/111) for Campylobacter 2 targeting Campylobacter coli and Campylobacter helveticus/upsaliensis , 58.1% (100/172) for Shigella /enteroinvasive Escherichia coli (EIEC), and 38.5% (100/260) for Salmonella spp. Positive predictive value (PPV) of FAGP based on culture and Xpert GI PCR Panel was 100% (42/42) for C. jejuni , 16.7% (4/24) for Campylobacter 2, 94.1% (16/17) for Shigella /EIEC, and 73.2% (30/41) for Salmonella spp. Inclusion of melt curve analysis had no impact on the sensitivity but significantly improved the specificity for Campylobacter spp. from 75% (60/80) to 100% (80/80; P < 0.001), Shigella /EIEC from 98.0% (49/50) to 100% (50/50; P > 0.05), and for Salmonella spp. from 78.0% (39/50) to 96% (48/50; P < 0.01). PPV for Norovirus was 7.6% (7/92) for Norovirus 1 and 76.0% (73/96) for Norovirus 2. Melt curve analysis improved accuracy for Norovirus 2 (sensitivity 100% [73/73] to 98.6% [72/73; P > 0.05]; specificity 79.8% [91/114] to 98.2% [112/114; P < 0.001]) but not for Norovirus 1 (sensitivity 100% [7/7] to 28.6% [2/7; P < 0.01]; specificity 52.0% [92/177] to 100% [177/177; P < 0.001]). FAGP has a high unconfirmed-positive rate for Campylobacter spp., Shigella /EIEC, and Salmonella spp. and Norovirus, which can be partially mitigated with melt curve analysis. IMPORTANCE The BioFire FilmArray Gastrointestinal Panel is a widely used syndromic panel for rapid diagnosis of gastroenteritis, but recent studies have shown an alarming rate of false-positive results for Norovirus, and concerns have been raised for Campylobacter spp. and other bacterial targets. This study found substantial rates of unconfirmed positive results with the FilmArray Gastrointestinal Panel for Campylobacter spp., Shigella /enteroinvasive Escherichia coli (EIEC), and Salmonella spp. in addition to Norovirus. Through defining specific melt curve parameters, this study shows that it is possible to mitigate unconfirmed positives and assure the quality of results fully for Campylobacter spp., Shigella /EIEC, and Salmonella spp. and partially for Norovirus.
ABSTRACT Bacteroides fragilis strains are important members of the human gut microbiota and represent major opportunistic pathogens responsible for a wide range of anaerobic infections. Their clinical relevance is reinforced by diverse antimicrobial resistance mechanisms and a complex population structure comprising two major phylogenetic lineages, Division I and Division II. Although whole-genome sequencing is increasingly used for bacterial surveillance, no standardized core genome multilocus sequence typing (cgMLST) scheme is available for B. fragilis , limiting high-resolution and comparable genomic analyses. In this study, we developed a cgMLST scheme comprising 2,342 highly conserved loci applicable across both Divisions. The scheme was developed from 433 publicly available genomes with diverse geographic origins, sample types, and isolation periods. It was subsequently evaluated using 118 newly sequenced infection-associated isolates from France not included in scheme development. Clustering analysis identified an accurate single-linkage threshold of 400 allelic mismatches, providing balanced resolution for population structure analyses and high concordance with core genome phylogeny and classical MLST sequence types. Well-defined clusters were identified within both Divisions, with genetic profiles indicative of long-standing evolutionary divergence. These clusters showed no clear association with geographic origin, isolation source, or sampling period. Notably, some clusters were enriched in nim -positive and multidrug-resistant (MDR) isolates, including one in particular that emerged as a genetically divergent MDR-associated lineage within Division II. This cgMLST scheme provides a standardized and high-resolution framework for B. fragilis genotyping. Its implementation in the publicly accessible BIGSdb-Pasteur platform ( https://bigsdb.pasteur.fr/ ) will support global genomic surveillance and future epidemiological studies. IMPORTANCE Bacteroides fragilis strains hold a position of relevance within the human gut microbiota, as they represent a major cause of severe anaerobic infections. Defining genotypes is essential for tracking infections and monitoring the emergence and spread of antimicrobial resistance. In this study, we developed a core genome multilocus sequence typing scheme for B. fragilis and applied it to a large collection of isolates from diverse origins. Our results reveal a structured population with well-defined and genetically conserved clusters across both Divisions, consistent with a long-standing population structure. Notably, several clusters were enriched in antimicrobial resistance determinants and multidrug-resistant isolates. This study also provides an easy-to-use resource for global surveillance and future epidemiological investigations of this clinically important pathogen.
ABSTRACT Dermatophytes are fungi that invade keratin-containing tissues, causing superficial infections in hair, skin, and nails. Dermatophytosis is the most common fungal infection worldwide. The epidemiology of dermatophytes has undergone significant changes in recent decades, as have the tools available to diagnose and identify these pathogens. Here, we review the current epidemiology of dermatophytes, including the emergence of novel lineages, describe recent changes in taxonomy with the use of molecular approaches, and discuss the status of available diagnostic tools for dermatophytosis, with a focus on newer technologies.